Navigation Links
Tolerx Initiates Dosing of Otelixizumab, a Novel Type 1 Diabetes Agent, in DEFEND, a Phase 3 Clinical Trial
Date:8/6/2008

nts, which are not historical facts, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Reform Act"). Statements regarding the outcomes sought to be realized in the Phase 3 clinical trial, the possibility that otelixizumab may have the potential to change type I diabetes treatment paradigms, the anticipated progress and development of otelixizumab, in type 1 diabetes and other disease indications, are all forward-looking statements. Such forward-looking statements involve risks, uncertainties and other factors that may cause the actual performance or achievements of Tolerx to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Factors and risks that may impact management's expectations and affect the forward-looking statements shall include but not be limited to results of DEFEND and other future clinical studies, the ability to obtain regulatory approval for otelixizumab for type 1 diabetes or any other indication, the continuation of the collaboration with GSK, the introduction of competing therapies by other companies, and changes in the company's business plan or objectives. These statements reflect the view of Tolerx as of the date of this press release and should not be relied upon as reflecting the company's views at any date subsequent to this release. Tolerx undertakes no obligation to update or revise any forward-looking statements to reflect events or circumstances after the date of this press release.


'/>"/>
SOURCE Tolerx, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Tolerx Achieves Milestone with Completion of Phase Ib Clinical Study of TRX1 in Cutaneous Lupus Erythematosus
2. Tolerx Advancing Novel Type 1 Diabetes Agent into Phase III Clinical Trial Program Following End of Phase II FDA Meeting
3. Tolerx Announces Achievement of Milestones upon anti-CD4 Antibody Program Advancement and Initiation of Phase 1 Clinical Trial
4. Carrington Subsidiary DelSite Initiates Critical Toxicology Studies of Its Nasal Powder Bird Flu Vaccine
5. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
6. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
7. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
8. MedImmune Initiates Phase 2a Multi-Dose Study in Patients with Asthma
9. Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
10. Nuvelo Re-Initiates SONOMA-3 Trial of Alfimeprase in Patients With Catheter Occlusion
11. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... , Aug. 20, 2014  Glades Drugs, an independent ... is proud to announce its expansion into a new corporate ... will feature an 8,000-square-foot office space and state of the ... applications for 100 open positions for the new facility. ... Lantana Road will serve as the chain,s corporate headquarters and ...
(Date:8/20/2014)... Reportlinker.com announces that a new market research report ... Patient Scales Industry http://www.reportlinker.com/p01374301/Global-Patient-Scales-Industry.html ... markets for Patient Scales in US$ Thousand by ... Baby Scales, Chair Scales, and Under Bed Scales. ... US, Canada, Japan, Europe, Asia-Pacific, Latin America, and ...
(Date:8/20/2014)... 2014 Phase I Trial of ... KalVista Pharmaceuticals ("KalVista"), an ophthalmology company with ... that it has begun a Phase I, First in ... for the treatment of DME. The study,s Principal Investigator ... Institute, Joslin Diabetes Center; Harvard Medical School Department of ...
Breaking Medicine Technology:Glades Drugs Moves to New Corporate Headquarters, 100 Open Positions 2Global Patient Scales Industry 2Global Patient Scales Industry 3Global Patient Scales Industry 4Global Patient Scales Industry 5Global Patient Scales Industry 6Global Patient Scales Industry 7Global Patient Scales Industry 8Global Patient Scales Industry 9Global Patient Scales Industry 10Global Patient Scales Industry 11Global Patient Scales Industry 12Global Patient Scales Industry 13Global Patient Scales Industry 14Global Patient Scales Industry 15Global Patient Scales Industry 16Global Patient Scales Industry 17Global Patient Scales Industry 18Global Patient Scales Industry 19KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 2KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 3KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 4
... Medical ® today announced that it has closed on ... by Singapore-based Crescent Point Group, with existing investors, Maverick ... Ventures and Affinity Capital, making additional investments. Sami Sindi, ... board of directors. Moelis & Company acted as financial ...
... Jan. 9, 2012  MolecularHealth, a clinico-molecular informatics company, ... two next generation product lines that translate patient-specific ... scientific evidence into safer, more effective drug choices ... producing genomic information falling drastically and clinical data ...
Cached Medicine Technology:Uptake Medical Announces Successful Completion of Series C Financing 2MolecularHealth to Introduce Knowledge-Driven Solutions that Enhance Drug Safety and Enable Molecularly-Guided Treatment Decision Support 2MolecularHealth to Introduce Knowledge-Driven Solutions that Enhance Drug Safety and Enable Molecularly-Guided Treatment Decision Support 3
(Date:8/20/2014)... no secret that millions of Americans are struggling with ... Abuse, nearly 24 million Americans are using some form ... fact that the total number of users has increased ... struggle with substance abuse often feel there may never ... has released updated lists of substance abuse resources ...
(Date:8/20/2014)... 2014 A Missouri federal judge has remanded ... were treated with GranuFlo and NaturaLyte to the City of ... Baron and Budd. The judge rejected an assertion by the ... were invalid. (McGee, et al. v. Fresenius Medical Care North ... Medical Care, is the manufacturer of the dialysis products GranuFlo ...
(Date:8/20/2014)... -- Taking the widely used antibiotic clarithromycin ... causes, a new study suggests. Because millions of ... urgent confirmation, said the Danish researchers behind the study. ... and that guidelines for the use of the drug ... One heart expert wasn,t surprised by the finding, ...
(Date:8/20/2014)... Chemically extracted acellular allogeneic nerve, from which ... have been removed, reduced postoperative immune rejection. ... neural substrates and base materials, such as ... can provide a good scaffold in the ... allogeneic nerve, similar to autologous nerve transplantation, ...
(Date:8/20/2014)... Angeles, CA (PRWEB) August 20, 2014 If ... has found a cure for it. With extensive research on ... provider named ‘MetroMD’ claims to have perfected the art of ... you a brand new younger look with their revolutionary anti-aging ... secrets of the 21st century fountain of youth, the MD ...
Breaking Medicine News(10 mins):Health News:Re-Launched AbuseTreatmentCenters.net Offering New List of Substance Abuse Resources 2Health News:GranuFlo/NaturaLyte Case Remanded to State Court By Missouri Federal Judge, Baron and Budd Reports 2Health News:Antibiotic Might Raise Heart Risks for Some 2Health News:MetroMD Offers Revolutionary Anti-aging Hormone Therapy in Hollywood Area 2
... may indicate underlying disease, study finds , , FRIDAY, Aug. 8 ... play a pivotal role in increasing an older American,s risk ... a new report says. , Levels of adiponectin increase in ... the cardiovascular health of older people, according to the new ...
... Alaska The University of Alaska Fairbanks campus will be ... 12-14, 2008. , The biennial conference is organized in ... Arctic Region and brings together international participants to address ... host to the 2008 conference. , More than150 guests ...
... Delivers Cheer, Medication and Equipment to Young Patients and Helps ... Raise Money for Make-A-Wish ... general,availability of its train-themed "JR" autonomous mobile robot to children,s,hospitals ... the,national Make-A-Wish Foundation for each JR TUG that is deployed. ...
... 1-inch cut behind uterus and into woman,s body cavity ... they say may be the first operation of its ... Hospital/Columbia University Medical Center removed a woman,s gallbladder without ... as part of an ongoing clinical research trial, involved ...
... EDT, Thursday, ... August 14, PRINCETON, ... advanced wound care products,announced plans to release its second quarter 2008 results ... the Company will,hold a conference call that same day to discuss the ...
... Inc. (NYSE: HGR ) is pleased to ... Hanger Orthopedic Group, Inc. to "positive",from "stable." Moody,s ... "We are pleased with the outlook change ... the last ten quarters," remarked George McHenry,Hanger,s Chief ...
Cached Medicine News:Health News:Fat Cell Protein Boosts Heart Attack Risk in Elderly 2Health News:UAF to host Eighth Conference of Arctic Parliamentarians 2Health News:Charlotte Children's Hospital Gets a Delivery from Aethon's Train-Themed Robot This Fall 2Health News:Charlotte Children's Hospital Gets a Delivery from Aethon's Train-Themed Robot This Fall 3Health News:New Technique Removes Gallbladder Without External Incisions 2Health News:Derma Sciences Conference Call Advisory 2
... CMIS Telemetry System is a telemetry ... hospitals which require monitoring and performance. ... are able to monitor patients from ... transmitters and wireless bedsides. Now, monitoring ...
... Telemetry System, portable TeleMon companion monitor, ... integrated surveillance and monitoring solution for ... of ECG and SpO2. Clinicians can ... patient information from the central station, ...
TeleRehab Advantage is a monitoring system that automates the generation of outcomes data. Patient information and session information is automatically transferred from the monitoring program to Outc...
ISI DuraHand is the reusable, easy to sterilize surgical hand immobilizer....
Medicine Products: